Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Cost of Revenue: 2021-2023

Historic Cost of Revenue for Mereo BioPharma Group (MREO) over the last 3 years, with Dec 2023 value amounting to $2.6 million.

  • Mereo BioPharma Group's Cost of Revenue was N/A to $32,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $3.4 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2023, which is 124.61% up from last year.
  • As of FY2023, Mereo BioPharma Group's Cost of Revenue stood at $2.6 million, which was up 124.61% from $1.1 million recorded in FY2022.
  • In the past 5 years, Mereo BioPharma Group's Cost of Revenue registered a high of $24.1 million during FY2021, and its lowest value of $1.1 million during FY2022.
  • Moreover, its 3-year median value for Cost of Revenue was $2.6 million (2023), whereas its average is $9.3 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Cost of Revenue crashed by 95.25% in 2022 and then surged by 124.61% in 2023.
  • Mereo BioPharma Group's Cost of Revenue (Yearly) stood at $24.1 million in 2021, then slumped by 95.25% to $1.1 million in 2022, then skyrocketed by 124.61% to $2.6 million in 2023.